RBC Capital Reiterates Outperform on Viridian Therapeutics, Maintains $35 Price Target
Portfolio Pulse from Benzinga Newsdesk
RBC Capital analyst Gregory Renza has reiterated an Outperform rating on Viridian Therapeutics (NASDAQ:VRDN) and maintained a price target of $35.

November 14, 2023 | 5:09 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
RBC Capital analyst Gregory Renza reaffirmed an Outperform rating on Viridian Therapeutics with a $35 price target.
The reiteration of an Outperform rating by a major analyst like RBC Capital is a positive signal for investors, suggesting confidence in the company's future performance. The maintained price target of $35 indicates a belief that the stock has significant upside potential from its current level. This could lead to increased investor interest and a potential short-term rise in the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100